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Introduction: The current standard of care for good performance
status patients with locally advanced non-small cell lung carcinoma
is concurrent chemoradiation, although a clearly superior regimen
has not been identified. Docetaxel has been shown to possess good
single-agent activity against non-small cell lung cancer (NSCLC)
and radiosensitizing properties, both alone and synergistically with
carboplatin. We undertook this phase II study to determine the safety
and efficacy of weekly docetaxel-carboplatin and concurrent radia-
tion therapy followed by docetaxel-carboplatin consolidation for the
treatment of locally advanced NSCLC.
Methods: Sixty-seven patients having previously untreated stage
IIIA or IIIB unresectable NSCLC were enrolled, with 61 patients
evaluated for endpoints. Docetaxel 20 mg/m2 IV infusion over 30
minutes followed by carboplatin area under the curve  2 over 30
minutes was administered weekly during concurrent thoracic radio-
therapy. After 3 week rest, consolidation docetaxel 75 mg/m2 IV
infusion over 60 minutes and carboplatin area under the curve  6
over 30 minutes was administered every 3 weeks for two cycles.
Concurrent thoracic radiation consisted of 45 Gy (1.8 Gy fractions
5 d/wk for first 5 weeks) followed by 18 Gy boost (2.0 Gy fractions
5 d/wk for 2 weeks) for a total dose of 63 Gy.
Results: One and 2 years overall survival rates were 45 and 20%,
respectively. Progression free survival at 1 year was 27%. Median
survival time was 12 months. Median time to progression was 8
months. The primary hematologic toxicity was leukopenia. The
primary nonhematologic toxicity was esophagitis.
Conclusion: The administered regimen of weekly docetaxel-carbo-
platin and concurrent radiation therapy followed by docetaxel-
carboplatin consolidation has acceptable toxicity profile. However,
the overall survivals at 1 and 2 years are somewhat disappointing.
Key Words: Chemoradiation, NSCLC, Concurrent chemoradiation,
Consolidation, Chemoradiotherapy, Non-small cell lung cancer,
Docetaxel, Carboplatin.
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Lung cancer is the third most common noncutaneous neo-plasm and most common cause of cancer related deaths in
the United States.1 Non-small cell lung cancer (NSCLC)
represents approximately 75 to 80% of lung cancer cases, and
often presents at an advanced stage (stage III-IV) that is
usually beyond surgical intervention. Previously, the standard
of care for patients with such presentation was a 4 to 6 week
course of thoracic radiation therapy. It allows for excellent
local control of thoracic-related symptoms including hemop-
tysis, airway obstruction, dyspnea, and chest pain. However,
radiation therapy alone is limited in its long-term effective-
ness, with median survival times (MSTs) of less than 10
months after disease presentation, and 5-year survival rates of
5 to 8%.2 Such low survival emphasizes the need for novel
therapeutic regimens for the treatment of NSCLC. One strat-
egy is the use of chemotherapy and radiation with the intent
of rendering tumors resectable. However, when resection is
not an option the challenge becomes to maximize the remain-
ing therapeutic options to provide greater disease control and
increase overall survival.
Many novel clinical investigations have sought to im-
prove the survival of stage III NSCLC by combining chemo-
therapy with thoracic radiation. Early randomized trials failed
to show any clear benefit of combined chemotherapy/radiation
regimens over thoracic radiation alone. However, the introduc-
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tion of platinum-based chemotherapy regimens resulted in sig-
nificant survival advantages when combined with thoracic
radiation therapy versus radiation therapy alone. In patients
with locally advanced, unresectable stage III NSCLC, such
combinations resulted in MSTs of 13 to 14 months, and 5-year
survival rates as high as 15 to 20%, almost tripling survival from
radiotherapy alone.3–6 Furthermore, a number of trials and a
meta-analysis have shown that concurrent chemoradiation
affords superior outcomes compared with sequential chemo-
radiation when using similar chemotherapy regimens, al-
though the toxicity profile may be more severe in concurrent
therapy.7–11 Although no clearly superior treatment regimen
exists for advanced NSCLC, combined modality treatment—
particularly concurrent chemoradiation with a platinum-con-
taining agent—is the current standard of care for unresectable
stage III NSCLC. It is thought that the advantage conferred
by concurrent treatment is due to radiosensitizing effects of
chemotherapy and improved local control that translates into
clinically significant increases in overall survival.
To that end, a number of other chemotherapeutics have
been investigated for combined modality treatment. The tax-
anes are a novel class of chemotherapeutic agents that possess
good activity as single agents in the setting of NSCLC.12,13
The Locally Advanced Multimodality Protocol trial investi-
gated the use of taxanes through three separate arms of
sequential therapy, induction/concurrent therapy, or concur-
rent/consolidation therapy using a regimen of paclitaxel,
carboplatin, and thoracic radiation. Results showed a median
survival of 16.1 months for concurrent/consolidation arm,
12.7 months for induction/concurrent therapy, and 13.0 months
for sequential therapy.14 A number of other trials have investi-
gated the use of paclitaxel and carboplatin in combined modality
therapy for NSCLC with encouraging results and similar
MSTs.15–18
Docetaxel has a mechanism of action similar to pacli-
taxel in its ability to stabilize microtubules by promoting
microtubule assembly and inhibiting microtubule depolymer-
ization. Several preclinical studies have shown docetaxel and
paclitaxel to possess radiosensitizing effects.19–22 It is thought
that they exert their radiosensitizing effect by cell cycle syn-
chronization at the G2/M phase, a particularly radiosensitive
point of the cell cycle. However, docetaxel differs from
paclitaxel in a number of important ways. Although both
have been observed to induce p27, docetaxel causes greater
phosphorylation of the proapoptotic Bcl-2.23 Docetaxel exhib-
its activity in cisplatin-resistant and paclitaxel-resistant cell
lines,24–26 as well as higher uptake and accumulation in tumor
cells, greater affinity for microtubulin, and slower cyto-
plasmic efflux than paclitaxel.27–29 Docetaxel also pos-
sesses stronger antiangiogenic properties than paclitaxel.30
These observations have led to trials investigating
the safety and efficacy of docetaxel in multimodality
treatment. Trials have examined the use of docetaxel as
consolidation therapy,31,32 or for use in concurrent chemo-
radiation as single agent or part of platinum-containing
doublets.33–35 Here, we report the results of a phase II
study designed to explore the potential benefits of concur-
rent weekly docetaxel/carboplatin and thoracic radiation
therapy followed by consolidation docetaxel/carboplatin
on overall response rate, survival, progression-free sur-
vival, safety, and toxicity in patients with locally advanced
NSCLC.
PATIENTS AND METHODS
Patient Eligibility
Patients with histologically documented inoperable
stage IIIA or IIIB NSCLC without evidence of malignant or
exudative pleural effusion were eligible for this study. All
patients had measurable or assessable disease. Further eligi-
bility criteria included: patient age 18 years; Eastern Co-
operative Oncology Group performance status 1; no prior
chemotherapy or radiotherapy; platelet count 100,000/l;
absolute neutrophil count (ANC) 1500/l; hemoglobin 9
g/dl; total bilirubin within normal limits; aspartate transami-
nase or alanine aminotransferase could be up to 5  institu-
tional upper limit of normal (ULN) if alkaline phosphatase
was ULN, or transaminase level up to 1.5  ULN if
alkaline phosphatase is 2.5  ULN, or transaminase level
ULN if alkaline phosphatase is 5  ULN; a calculated
creatine clearance of 50 ml/min per Cockroft-Gault for-
mula; and a forced expiratory volume in 1 second 800 ml.
Exclusion criteria included: known hypersensitivity to drugs
formulated with polysorbate 80; peripheral neuropathy grade
2; any concomitant malignancy, brain metastasis, or uncon-
trolled, clinically significant medical or psychiatric disorder;
pregnant or nursing women; and weight loss 10% body
weight over prior 3 months. All patients signed an informed
consent and received medical oncology and radiation oncol-
ogy consult and approvals before study entry. Before initia-
tion of protocol therapy, all patients underwent a complete
history and physical examination; pretreatment laboratory
tests including complete blood cell count (CBC) with differ-
ential and platelet count, chemistry panel, and serum preg-
nancy tests for females of child-bearing potential; screening
12-lead electrocardiograph; assessment of lung function by
forced expiratory volume in 1 second; computed tomography
(CT) or magnetic resonance imaging (MRI) of chest and
upper abdomen to determine location, type, and size of
measurable lesions; and screening brain CT or MRI. Positron
emission tomography (PET) scanning was encouraged but
not required for protocol treatment.
Treatment Plan
Eligible patients received treatment in an outpatient
setting beginning with concurrent chemotherapy and radio-
therapy delivered over a 7-week period. CBCs including
differential and platelet counts were obtained weekly during
periods of active study treatment. In cases of grade 4 ANC,
minimum bi-weekly CBCs were obtained until documented
ANC recovery to  grade 1. Routine serum chemistries were
collected every 4 weeks during concurrent chemoradiation
and before the start of each consolidation chemotherapy
cycle. A chest CT or MRI scan was repeated before admin-
istration of consolidation chemotherapy. Full supportive care,
including transfusion of blood, blood products, antibiotics,
and antiemetics was provided.
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Chemotherapy
Docetaxel was administered as a 30-minute intravenous
infusion weekly starting on day 1 for 7 weeks as part of
concurrent therapy. Docetaxel was given at a dose of 20
mg/m2/wk. Patients were premedicated with dexamethasone
4 mg  3 doses, given 12 hours before docetaxel infusion, 1
hour before infusion, and 12 hours after infusion. Carboplatin
was administered as a 30-minute intravenous infusion during
concurrent therapy at a dose of area under the curve (AUC) 2
immediately after docetaxel infusion.
Consolidation chemotherapy was started after a 3-week
rest period after concurrent therapy. Docetaxel was given at a
dose of 75 mg/m2 once as a 1 hour intravenous infusion
followed by carboplatin AUC 6 given as a 30 minute intra-
venous infusion every 3 weeks for two cycles (1 cycle 
3-week period). Dexamethasone was given at a dose of 8 mg
PO beginning 24 hours before docetaxel administration
and every 12 hours thereafter for five doses. Antiemetic
therapy with 5-HT3 was given 60 minutes before consol-
idation chemotherapy.
Radiation Therapy
Radiation therapy began on day 1 of chemotherapy for
all patients, after infusions of docetaxel and carboplatin. The
target volume consisted of an original volume and a boost
volume. Volumes were based on a planning CT taken before
treatment. The original volume consisted of the complete
extent of visible primary tumor with margins of 2.0 to 2.5 cm;
lymph nodes in the original volume included ipsilateral hi-
lum, superior mediastinum, and subcarinal nodes with mar-
gins of 2.0 cm. The ipsilateral supraclavicular nodes were
included only for primary tumors involving the upper lobes
and/or mainstream bronchus lesions. Inferior mediastinal
nodes were included for patients with primary disease of
lower lobe(s) or inferior mediastinal involvement. Contralat-
eral lymph nodes were only included in patients with medi-
astinal, subcarinal, or contralateral hilar involvement. The
boost volume consisted of the primary tumor volume, in-
volved nodes, and nodes2.5 cm in diameter only. Radiation
therapy was delivered to the original volume as a total dose
of 45.0 Gy administered as 1.8 Gy daily fractions 5 days a week
over 5 weeks, followed by an additional 18.0 Gy to the boost
volume delivered as daily 2.0 Gy fractions. Total dose was 63.0
Gy in 34 fractions over 7 weeks. The maximal dose allowed to
any point in the spinal cord was 49 Gy.
Response and Toxicity Criteria
All toxicities were graded using National Cancer Insti-
tute Common Toxicity Criteria, version 2.0. Assessment of
disease response occurred before cycle 1 of consolidation
therapy and 2 months after completion of consolidation
therapy, or at any time clinical signs were suggestive of
progressive disease (PD). Patients with PD before consolida-
tion were taken off study. Complete response was defined as
the disappearance of all measurable and evaluable disease for
at least 4 weeks. Partial response required a reduction of 50%
in the sum of the products of the perpendicular diameters of
all measurable lesions, or a 50% decrease (for assessable dis-
ease) lasting at least 4 weeks in the area of the tumor mass
estimated by two independent observers.
Dose Modifications
No more than one dose modification of docetaxel and
carboplatin (concurrent therapy reduced to 15 mg/m2/wk and
AUC 1.5, consolidation therapy reduced to 56 mg/m2 and AUC
5) was allowed for any patient during therapy. If reduced, dose
was not reescalated for subsequent dosages or cycles.
Statistical Methods
Sample size estimation was completed using a log-rank
test. MST for the historical control group was estimated as 17
months. Using a two-sided type I error rate 5%, 84 patients
were needed to detect relative risk of 1.65 between historical
control group and this study with 80% power. This power
analysis was based on the assumptions that accrual time was
approximately 18 months with additional 3 years follow-up
time. With an assumed dropout rate of 5% in this study, final
sample size was determined to be 80 patients. Overall sur-
vival was measured using the Kaplan-Meier method. Statis-
tical analyses were completed suing S-Plus 6 and/or SAS
statistical software.
RESULTS
Patient Characteristics
Between October 2004 and January 2007, 67 patients
with locally advanced stage IIIA or IIIB NSCLC were en-
rolled in this study. Of the original 67 patients, 63 were
deemed evaluable. Characteristics are summarized in Table 1.
The sample consisted of 37 men and 26 women, with a
median age of 64 years, ranging from 48 to 83 years. The
majority of patients were white (82%) followed by African
TABLE 1. Characteristics of Enrolled Patients
Number (%)
No. patients 67
Age (yr)
Median 64.2
Range 48–83
Sex
Male 40 (60)
Female 27 (40)
Baseline PS
PS  0 28 (42)
PS  1 39 (58)
Histology
Squamous 14 (21)
Adenocarcinoma 19 (28)
Large cell 2 (3)
Poorly differentiated 6 (9)
Unclassified 19 (39)
Stage
IIIA 32 (48)
IIIB 35 (52)
PS, performance status.
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American (12%). Twenty-seven patients (42%) had a base-
line Eastern Cooperative Oncology Group performance sta-
tus 0, whereas 36 patients (58%) had performance status
1. Approximately 48% of patients presented with stage IIIA
disease, whereas 52% of patients had stage IIIB disease. The
most common histologies were adenocarcinoma and squa-
mous cell carcinomas.
Response, Survival, and Patterns of Failure
Approximately 75% of enrolled patients completed the
entire protocol treatment including concurrent chemoradia-
tion and all cycles of consolidation chemotherapy. Patients
with PD during treatment were removed from protocol treat-
ment but included in response analysis. Patients were also
removed from protocol treatment if during treatment toxicity
was deemed to be intolerable to the patient, or if unrelated
medical circumstance dictated need for removal, but patients
were followed with intent-to-treat. Two patients were not
evaluable because of withdrawal before initiation of protocol
treatment and not included in statistical calculations. The
final number of patients evaluated for response was 61
patients. Of patients evaluable for response, 11% (7 of 61)
showed a complete response to treatment, whereas 56% (34
of 61) showed a partial response. Approximately 10% (6 of
61) showed PD, and 23% (14 of 61) showed stable disease.
The MST was approximately 12 months (95% confi-
dence interval 10.8–13.2 months). The median time to dis-
ease progression was approximately 8 months. One and 2
years overall survival was 45 and 20%, respectively. Progres-
sion-free survival at 1 year was 27%. Unresolved pleural or
pericardial effusions were considered evidence of PD for
response evaluation, at the discretion of the treating physi-
cian, irrespective of the subsequent outcome. Kaplan-Meier
plots of progression-free survival and overall survival are
shown in Figures 1 and 2, respectively.
There were 44 reported sites of failure. Among these,
22 (50%) were distant failures. Five failures occurred in the
brain, representing 11% of first failure, or 23% of patients
with distant sites of first failure. Six (14%) were both local
and distant failures and 16 (36%) were local-regional failures.
Toxicity
All toxicities were assessed using the National Cancer
Institute Common Toxicity Criteria version 2.0. Hematologic
and nonhematologic toxicities are summarized in Table 2.
Concurrent chemoradiation was generally well tolerated.
Both leucopenia and neutropenia was relatively uncommon
during concurrent or consolidative chemotherapy. Grade 3 or
higher, leucopenia occurred most frequently (approximately
16%) followed by neutropenia (approximately 13%). Of
nonhematologic toxicities, esophagitis of grade 3 or higher
occurred in approximately 22% of patients. Pneumonitis was
documented in three patients, all at grade 3. There was one
potential grade 5 GI toxicity that is not verifiable because of
lack of autopsy, however, treating physicians felt toxicity was
unrelated to treatment and instead to PD. There were no
episodes of grade 3 or higher neuropathy.
FIGURE 1. Kaplan-Meier plot of progression-free survival.
Median time to disease progression was approximately 8
months.
FIGURE 2. Kaplan-Meier plot of overall survival.
TABLE 2. Hematologic and Nonhematologic Toxicities
Acute Toxicity
Grade
>Grade 3 (%)2 3 4 5
Hematologic
Anemia 10 4 0 5.97
Leukopenia 4 9 2 16.42
Lymphopenia 2 2 1 4.48
Neutropenia 2 4 5 13.43
Transfused: platelets 2 2.99
Nonhematologic
Allergy 9 1 1.49
Skin 1 1.49
Dysphagia-esophagitis 2 12 3 22.39
Nausea 8 1 1.49
Vomiting 1 3 4.48
Diarrhea 1 1 1.49
GI-other 2 2 1 7.46
Infections 1 2 1 4.48
Pneumonitis ? 3 4.48
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DISCUSSION
The treatment of locally advanced NSCLC remains a
significant challenge to the clinician. Although a number of
significant advances have been made in multimodality treat-
ment of NSCLC, no clearly superior option has emerged for
unresectable NSCLC. It is generally accepted that concurrent
chemoradiation is the current standard of care, especially for
patients with good performance status. However, there are
many questions that remain to be answered, including the role
of induction and consolidation chemotherapy. We undertook
this study to investigate the safety and efficacy of a docetaxel-
carboplatin doublet with concurrent thoracic radiation and
consolidation docetaxel-carboplatin for the treatment of stage
IIIA or IIIB NSCLC.
A number of trials have investigated the use of docetaxel
and concurrent thoracic radiation therapy. Phase I studies have
established 30 mg/m2 docetaxel as the recommended dosage for
use as single agent with concurrent radiation.34,36,37 Phase I
investigations of weekly docetaxel-carboplatin doublet che-
motherapy and concurrent radiation recommended a lower
dosage of docetaxel at 20 mg/m2 and carboplatin AUC 2 to
maintain an acceptable toxicity profile.35,38,39 We employed
this dosage for use with concurrent thoracic radiation therapy,
followed by 75 mg/m2 docetaxel and carboplatin AUC  6
for consolidation. One and 2 years overall survival rates were
45 and 20%, respectively. Progression free survival at 1 year
was 27%. MST was 12 months. Median time to progression
was 8 months. This outcome is less than anticipated for stage
III NSCLC with combined modality therapy.
The use of induction or consolidation chemotherapy
remains controversial. Two nonrandomized Southwest On-
cology Group (SWOG) trials (9019, 9504) with identical
enrollment criteria investigated the efficacy and safety of a
cisplatin-etoposide chemotherapy regimen with concurrent
thoracic radiation.31,40 They differed in that SWOG 9019
followed concurrent therapy with cisplatin-etoposide consol-
idation, whereas 9504 used a three cycle docetaxel consoli-
dation regimen. SWOG 9019 had a reported MST of 15
months and 5-year survival rate of 15%. However, SWOG
9504 had a MST of 26 months and a 5-year survival of 29%.
It seemed that docetaxel consolidation conferred a significant
and impressive advantage in survival. However, a recent
phase III trial, HOG LUN 01-24/USO-023 randomized pa-
tients to cisplatin/etoposide concurrent chemoradiation and
either docetaxel consolidation or observation, with primary
endpoints of survival, and secondary endpoints of progres-
sion free survival and toxicity.41 The results of this trial
showed a median survival and 3-year survival rate of 24.1
months and 27.6% in the observation arm, and 21.5 months
and 27.2% in the docetaxel arm, respectively. Additionally,
there were significantly higher rates of febrile neutropenia,
infection, pneumonitis, and hospitalizations in the docetaxel
arm, thus bringing into question the efficacy and toxicity of
docetaxel consolidation. The dosage of docetaxel used in the
SWOG study was initially 75 mg/m2, and allowed for dose
escalation up to 100 mg/m2 during the second and third
cycles, whereas the HOG study used 75 mg/m2 for three
cycles.
In comparison, consolidation docetaxel-carboplatin has
had limited evaluation. Sakai et al.42 conducted a phase I/II
investigation of bi-weekly docetaxel/carboplatin (30 mg/m2
and AUC 3)and concurrent TRT followed by consolidation
docetaxel-carboplatin at same dosage. Results were encour-
aging with MST of 27 months, and 61% survival at 2 years,
but more follow-up is needed. Our trial investigated the
administration of docetaxel and carboplatin at dosages of 20
mg/m2 and AUC  2 during concurrent thoracic radiation
followed by consolidation at dosage of 75 mg/m2 and AUC 
6. The trials differed in a number ways. First, our trial evaluated
a greater number of patients than the Sakai trial (61 versus 33
patients). Our results significantly differed in results of re-
sponse and overall survival. There are a number of possible
reasons for this difference. One potential factor is the accu-
racy in staging. Our trial enrolled during the PET era, unlike
the Sakai trial. Our trial did not require PET scanning for
enrollment, however, over 50% of patients enrolled in our
trial were staged by PET, and of those staged by PET, there
were approximately equal numbers of stage IIIA and IIIB
patients. It is unlikely that the patients who did not receive
baseline PET scanning were understaged. The Sakai trial
enrolled a relatively high proportion of stage IIIB patients,
equally distributed between T4 and N3 staging. Our trial had
an approximately equal distribution between IIIA and IIIB
patients, and of IIIB patients there was a slightly higher
proportion of T4 staging as opposed to N3 staging. Our
results were somewhat disappointing compared with the Sa-
kai trial. It is possible that the higher dosages used during
concurrent chemoradiation in their trial contributed to greater
local control and impacted progression free and overall sur-
vival. However, the low number of patients evaluated in the
Sakai trial argue against an absolute benefit. We used a higher
dosage during the consolidation phase, still resulting in un-
acceptable response and survival. The advent of PET staging
during the accrual of this trial would be expected to decrease
the likelihood of previously unrecognized stage IV patients
inadvertently entering the trial. There is no clear reason to
explain the discrepancy in results between these two trials
other than the lower sample size of the previous trial. Still,
similar conclusions from these trials are reached in that the
concurrent chemoradiation using traditionally available cyto-
toxic agents has unfortunately reached a plateau, highlighting
the need for greater resources and investigation into novel
treatment combinations, including targeted therapeutics.
In conclusion, our trial reported suboptimal response and
overall survival outcomes. The regimen has acceptable toxicity
profile, yet the overall survival and progression free survival is
rather disappointing. This regimen does not seem to be active
and we are not pursuing further investigation.
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